NCT03156478 STOP DIABETES - Knowledge-based Solutions
| NCT ID | NCT03156478 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Eastern Finland |
| Condition | Type2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2017-04-10 |
| Primary Completion | 2018-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10,000 participants in total. It began in 2017-04-10 with a primary completion date of 2018-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the Stop Diabetes - Knowledge based solutions (StopDia) consortium project (University of Eastern Finland, National Institute for Health and Welfare, and Technical Research Centre of Finland) is to develop and test approaches to identify individuals at increased risk of type 2 diabetes and to empower them in adopting and maintaining a healthy lifestyle by combining individual and environment level strategies into a dual-process approach targeting deliberative and automatic processes of behavior. We also aim to identify barriers and facilitators of adopting a healthy lifestyle in the society, create a model for the prevention of type 2 diabetes by joint actions of health care, third sector, and other societal actors, and develop methods to monitor the cost-effectiveness of these actions. We will carry out a 1-year randomized controlled trial on the effects of among 10 000 individuals aged 18-70 years at increased risk of type 2 diabetes living in Finland. The participants will be randomized into the control group, the digital lifestyle intervention group, or the combined digital and face-to-face lifestyle intervention group. The aim of the interventions is to enhance diet quality, increase physical activity, decrease body weight, and improve glucose tolerance in individuals at increased risk of type 2 diabetes.
Eligibility Criteria
Inclusion Criteria: * age of 18-70 years * 12 points or more in the Finnish diabetes risk score or previous gestational diabetes or repeated impaired fasting glucose (IFG) (fasting plasma glucose level 6,1 - 6,9 mmol/l) or impaired glucose tolerance (2-hour glucose level 7,8 - 11,0 mmol/l in oral glucose tolerance test) * living in the hospital district of Northern Savo, Päijät-Häme or South Karelia * possibility to use computer, smartphone or tablet with internet connection * having own self-phone number * adequate Finnish language skill Exclusion Criteria: * type 1 or 2 diabetes * pregnancy or breastfeeding * current cancer or less than 6 months from the end of cancer treatment
Contact & Investigator
Jussi Pihlajamäki, MD, PhD
PRINCIPAL INVESTIGATOR
University of Eastern Finland
Frequently Asked Questions
Who can join the NCT03156478 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Type2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03156478 currently recruiting?
Yes, NCT03156478 is actively recruiting participants. Contact the research team at jussi.pihlajamaki@uef.fi for enrollment information.
Where is the NCT03156478 trial being conducted?
This trial is being conducted at Kuopio, Finland.
Who is sponsoring the NCT03156478 clinical trial?
NCT03156478 is sponsored by University of Eastern Finland. The principal investigator is Jussi Pihlajamäki, MD, PhD at University of Eastern Finland. The trial plans to enroll 10,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.